Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Laboratorio Dominguez markets two Vitamin D supplements under the DENURIX brand: DENURIX (ergocalciferol/Vitamin D2) and DENURIX D3 (cholecalciferol/Vitamin D3). These oral small molecule supplements act as agonists of the Vitamin D receptor (VDR). Upon ingestion, they are metabolized to their active forms (e.g., calcitriol), which bind to the VDR in the nucleus of target cells. This activation regulates calcium and phosphate homeostasis, promoting intestinal calcium absorption and maintaining bone mineralization. They are indicated for the treatment and prevention of Vitamin D deficiency and the management of osteoporosis in Argentina.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ergocalciferol + cholecalciferol (Laboratorio Domínguez).